Infectious Disease Research Institute (IDRI)

58 articles with Infectious Disease Research Institute (IDRI)

• Infectious Disease Research Institute Exits Receivership and Launches AAHI, the Access to Advanced Health Institute, with $50 Million Funding Commitment

  3/2/2022

  The Infectious Disease Research Institute announced that it has exited receivership and is resuming independent operation as the Access to Advanced Health Institute, to better reflect the organization’s renewed focus and evolving mission to protect and improve lives and health around the world.

• 

  Mix-and-Match Vaccine Platform May Boost Immune Response & Duration

  12/3/2021

  IDRI is working with a newly-formed consortium to develop a next-gen COVID-19 vaccine that will be stable at routine temperatures and that may be able to confer immunity for a longer duration.

• Amyris Completes First Major License For Leading RNA Vaccine Advancing Technology To Human Trials

  7/1/2021

   Amyris, Inc. today announced that it has signed an exclusive license with Nant Africa , LLC relating to the development and use of the RNA Covid vaccine Amyris devloped in coordination with the Infectious Disease Research Institute.

• 

  Research Roundup: Neuronal Cell Death in Alzheimer’s and More

  5/14/2021

  Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

• New Adjuvanted Vaccine Candidate Using IDRI Formulation Demonstrates Coronavirus Pan-Vaccine Potential

  5/10/2021

  The Infectious Disease Research Institute, Duke Human Vaccine Institute, and 3M have collaborated to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2, as well as other coronaviruses.

• 

  New COVID-19 Vaccine on the Block Displays Multi-Variant Potential

  5/10/2021

  The Infectious Disease Research Institute (IDRI), Duke Human Vaccine Institute, and 3M are working together on a potential vaccine that might protect individuals against multiple variants of SARS-CoV-2.

• Amyris and The Infectious Disease Research Institute Enter into Exclusive License for Novel RNA Vaccine Platform, Beginning with COVID-19 Vaccine

  10/22/2020

  Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced the signing of a Collaboration Agreement and License Agreement with the Infectious Disease Research Institute

• Amyris and The Infectious Disease Research Institute Partner to Advance Novel RNA Vaccine Platform Beginning With COVID-19 Application

  7/27/2020

   Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets and IDRI (Infectious Disease Research Institute) today announce the signing of a binding term sheet for a planned COVID-19 RNA (ribonucleic acid) vaccine technology program. The program combines IDRI's expertise in combating i

• Infectious Disease Research Institute (IDRI) Release: Promising New Leprosy Vaccine Moves Into Human Trials

  10/12/2017

• Infectious Disease Research Institute (IDRI) To Continue Development Of Inhalable TB Drug Candidate

  8/24/2017

• Infectious Disease Research Institute (IDRI) Receives $15 Million Commitment From Eli Lilly For TB Drug Discovery

  11/3/2016

• Infectious Disease Research Institute (IDRI) Receives FDA Grant To Develop RNA-Based Zika Virus Vaccine

  10/7/2016

• Infectious Disease Research Institute (IDRI) Adds Viral Vaccine Development Expertise; Expands Leadership

  4/13/2016

• Infectious Disease Research Institute (IDRI) And Sanofi Pasteur Team With Philanthropy To Develop New Model For Vaccine Development

  10/15/2015

• Infectious Disease Research Institute (IDRI) And Wellcome Trust Team For Tuberculosis Vaccine Trial In South Africa

  9/17/2015

• Amyris, Inc. And Infectious Disease Research Institute (IDRI) Announce Agreement To Explore Testing And Development Of Amyris Materials For Use In Vaccine Adjuvant Formulations

  9/9/2015

• Infectious Disease Research Institute (IDRI) Announces $4M Biomedical Advanced Research and Development Authority (BARDA) Cooperative Agreement To Establish Adjuvant Hub

  2/19/2015

• Infectious Disease Research Institute (IDRI) Announces $11.9M Contract To Develop Thermostable TB Vaccine

  11/20/2014

• Infectious Disease Research Institute (IDRI) Announces $11.9M Contract To Develop Thermostable TB Vaccine

  11/19/2014

• Infectious Disease Research Institute (IDRI) and Zydus Sign Agreement for Development of IDRI's Vaccine Candidate for Visceral Leishmaniasis (Kala-Azar)

  7/25/2013